EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, IGM Biosciences's enterprise value is €271.36 Mil.
IGM Biosciences's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was €-226.65 Mil. Therefore, IGM Biosciences's EV-to-EBITDA for today is -1.20.
The historical rank and industry rank for IGM Biosciences's EV-to-EBITDA or its related term are showing as below:
STU:1K0'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -3.43 Med: -1.27 Max: 0.41
Current: -1.21
During the past 7 years, the highest EV-to-EBITDA of IGM Biosciences was 0.41. The lowest was -3.43. And the median was -1.27.
STU:1K0's EV-to-EBITDA is ranked worse than 100% of 459
companies
in the Biotechnology industry
Industry Median: 10.28
vs STU:1K0: -1.21
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
IGM Biosciences EV-to-EBITDA Historical Data
The historical data trend for IGM Biosciences's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of IGM Biosciences's EV-to-EBITDA
For the Biotechnology subindustry, IGM Biosciences's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IGM Biosciences's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, IGM Biosciences's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where IGM Biosciences's EV-to-EBITDA falls into.
IGM Biosciences's current Enterprise Value is €271.36 Mil.
IGM Biosciences's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-226.65 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
IGM Biosciences's PE Ratio for today is calculated as:
IGM Biosciences's share price for today is €8.60.
IGM Biosciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-3.957.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of IGM Biosciences's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, IGM-2323, is a bispecific T cell engaging IgM antibody targeting CD20 and CD3 protein, IGM-8444, a combination with a chemotherapeutic agent such as irinotecan, gemcitabine, or venetoclax, and IGM-7354, a bispecific IgM antibody delivering interleukin-15 (IL-15) cytokines to PD-L1 expressing cells for the treatment of patients with solid and hematologic malignancies.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
STU:1K0 has been successfully added to your 